Wojciech Jurczak

ASCEND Phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) (2158)

Wojciech Jurczak

Click the following button to download this presentation’s slides

Bio Ascend LLC
980 N Michigan Avenue, Suite 1400
Chicago, IL 60611
(p) 1-888-476-9129 (US toll-free)
(f) 312-277-6893
iwCLL2019@bioascend.com

2019 Presentations Access

Thank you for your interest in viewing the iwCLL 2019 video presentations.
Please complete the following information below to access the presentations.

First Name*
Last Name*
Email Address*
Country*
Degree
Institution
Would you like to opt in to receive more about future iwCLL activities and/or Bio Ascend educational activities?*
- Yes
- No
CAPTCHA

* required fields